High White Blood Cell Count is Associated with a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes
Overview
Authors
Affiliations
Chronic low-grade inflammation may be involved in the pathogenesis of insulin resistance and type 2 diabetes. We examined whether a high white blood cell count (WBC), a marker of inflammation, predicts a worsening of insulin action, insulin secretory function, and the development of type 2 diabetes in Pima Indians. We measured WBC in 352 nondiabetic Pima Indians (215 men and 137 women, aged 27 +/- 6 years [means +/- SD], body fat 32 +/- 8%, WBC 8,107 +/- 2,022 cells/mm(3)) who were characterized for body composition (by hydrodensitometry or dual-energy X-ray absorptiometry), glucose tolerance (by 75-g oral glucose tolerance test), insulin action (M; by hyperinsulinemic clamp), and acute insulin secretory response (AIR; by 25-g intravenous glucose challenge). Among 272 subjects who were normal glucose tolerant (NGT) at baseline, 54 developed diabetes over an average follow-up of 5.5 +/- 4.4 years. Among those who remained nondiabetic, 81 subjects had follow-up measurements of M and AIR. Cross-sectionally, WBC was related to percent body fat (r = 0.32, P < 0.0001) and M (r = -0.24, P < 0.0001), but not to AIR (r = 0.06, P = 0.4). In a multivariate analysis, when adjusted for age and sex, both percent body fat (P < 0.0001) and M (P = 0.03) were independently associated with WBC. A high WBC value predicted diabetes (relative hazard 90th vs. 10th percentiles [95%CI] of 2.7 [1.3-5.4], P = 0.007) when adjusted for age and sex. The predictive effect of WBC persisted after additional adjustment for established predictors of diabetes, i.e., percent body fat, M, and AIR (relative hazard 2.6 [1.1-6.2], P = 0.03). After adjustment for follow-up duration, a high WBC at baseline was associated with a subsequent worsening of M (P = 0.003), but not a worsening of AIR. A high WBC predicts a worsening of insulin action and the development of type 2 diabetes in Pima Indians. These findings are consistent with the hypothesis that a chronic activation of the immune system may play a role in the pathogenesis of type 2 diabetes.
Bibi S, Naeem M, Schipf S, Bahls M, Dorr M, Friedrich N Eur J Clin Invest. 2025; 55(4):e70005.
PMID: 39921528 PMC: 11891827. DOI: 10.1111/eci.70005.
Zhou J, Yin S, Du L, Xue X, He Q, Zhao N Nutrients. 2025; 17(1.
PMID: 39796481 PMC: 11723060. DOI: 10.3390/nu17010047.
Upadhyayula S, Ubaru S, Raajeshwi P, Ajavindu C, Rao A Cureus. 2025; 16(12):e75196.
PMID: 39759667 PMC: 11700368. DOI: 10.7759/cureus.75196.
Basson-Shleymovich Y, Yahalom-Peri T, Azmon M, Cukierman-Yaffe T J Clin Med. 2024; 13(23).
PMID: 39685547 PMC: 11642438. DOI: 10.3390/jcm13237089.
Sun X, Zhu J, Qian Z, Chen X, Zhang J, Ji C J Inflamm Res. 2024; 17:10613-10626.
PMID: 39664170 PMC: 11633290. DOI: 10.2147/JIR.S491694.